GLP1R and coronary artery disorder: These peptides target receptors implicated in CAD pathophysiology, such as angiotensin II type 1 receptor (AT1R), glucagon-like peptide-1 receptor (GLP-1R), and interleukin-6 receptor (IL-6R).